The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It

Armstrong, Heather; Bording-Jorgensen, Michael; Dijk, Stephanie; Wine, Eytan

doi:10.3390/cancers10030083

Cited by 97 publications

(86 citation statements)

References 276 publications

(352 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To define specific microbial signatures for BC patients may also have implications for future diagnostic development as well as for therapeutic interventions [98]. …”

Section: Discussionmentioning

confidence: 99%

Breast Cancer and Its Relationship with the Microbiota

Fernández

Reina-Pérez

Astorga

et al. 2018

IJERPH

264

197

View full text Add to dashboard Cite

The microorganisms that live symbiotically in human beings are increasingly recognized as important players in health and disease. The largest collection of these microorganisms is found in the gastrointestinal tract. Microbial composition reflects both genetic and lifestyle variables of the host. This microbiota is in a dynamic balance with the host, exerting local and distant effects. Microbial perturbation (dysbiosis) could contribute to the risk of developing health problems. Various bacterial genes capable of producing estrogen-metabolizing enzymes have been identified. Accordingly, gut microbiota is capable of modulating estrogen serum levels. Conversely, estrogen-like compounds may promote the proliferation of certain species of bacteria. Therefore, a crosstalk between microbiota and both endogenous hormones and estrogen-like compounds might synergize to provide protection from disease but also to increase the risk of developing hormone-related diseases. Recent research suggests that the microbiota of women with breast cancer differs from that of healthy women, indicating that certain bacteria may be associated with cancer development and with different responses to therapy. In this review, we discuss recent knowledge about the microbiome and breast cancer, identifying specific characteristics of the human microbiome that may serve to develop novel approaches for risk assessment, prevention and treatment for this disease.

show abstract

“…To define specific microbial signatures for BC patients may also have implications for future diagnostic development as well as for therapeutic interventions [98]. …”

Section: Discussionmentioning

confidence: 99%

Breast Cancer and Its Relationship with the Microbiota

Fernández

Reina-Pérez

Astorga

et al. 2018

IJERPH

264

197

View full text Add to dashboard Cite

show abstract

“…Based on recent studies, the microbiome is a risk factor for BC and an explanation for different responses to therapy (9). The question that arises is "How can microbiome affect BC risk; in which mechanisms they detain or improve different therapeutic approaches; and what are the effects of probiotics on breast cancer management?…”

Section: Introductionmentioning

confidence: 99%

Microbiome and Breast Cancer: New Role for an Ancient Population

et al. 2020

View full text Add to dashboard Cite

There are many risk factors associated with breast cancer (BC) such as the familial history of BC, using hormone replacement therapy, obesity, personal habits, and other clinical factors; however, not all BC cases are attributed to these risk factors. Recent researches show a correlation between patient microbiome and BC suggested as a new risk factor. The present review article aimed at evaluating the role of the microbiome as a risk factor in the occurrence of BC, investigating the proposed mechanisms of interaction between the microbiome and human genes involved in BC, and assessing the impact of the altered composition of breast, gut, and milk microbiome in the physiological status of normal breast as well as cancerous or non-cancerous breast lesions. The study also evaluated the growing evidence that these altered populations may hinder chemotherapeutic treatment. The role of microbiome in the development and maintenance of inflammation, estrogen metabolism, and epigenetic alterations was properly investigated. Finally, clinical and therapeutic applications of the microbiome-e.g., probiotics, microbiome genome modulation, and engineered microbiome enzymes in the management of BC were reviewed.

show abstract

“…Previous studies have demonstrated that inflammation and prostatic infection can promote prostate tumorigenesis . A recent population‐based retrospective cohort study in 13,453 patients with ischemic cardio‐ or cerebrovascular disease demonstrates that use of low‐dose aspirin twice or more per week correlates with a lower risk of prostate cancer .…”

Section: Epidemiological Evidence For the Prevention Of Cancer By Aspmentioning

confidence: 99%

Complex roles of the old drug aspirin in cancer chemoprevention and therapy

Hua

Zhang

Kong

et al. 2018

Medicinal Research Reviews

View full text Add to dashboard Cite

The nonsteroidal anti-inflammatory agent aspirin is widely used for preventing and treating cardiovascular and cerebrovascular diseases. In addition, epidemiologic evidences reveal that aspirin may prevent a variety of human cancers, while data on the association between aspirin and some kinds of cancer are conflicting. Preclinical studies and clinical trials also reveal the therapeutic effect of aspirin on cancer. Although cyclooxygenase is a well-known target of aspirin, recent studies uncover other targets of aspirin and its metabolites, such as AMP-activated protein kinase, cyclin-dependent kinase, heparanase, and histone. Accumulating evidence demonstrate that aspirin may act in different cell types, such as epithelial cell, tumor cell, endothelial cell, platelet, and immune cell. Therefore, aspirin acts on diverse hallmarks of cancer, such as sustained tumor growth, metastasis, angiogenesis, inflammation, and immune evasion. In this review, we focus on recent progress in the use of aspirin for cancer chemoprevention and therapy, and integratively analyze the mechanisms underlying the anticancer effects of aspirin and its metabolites. We also discuss mechanisms of aspirin resistance and describe some derivatives of aspirin, which aim to overcome the adverse effects of aspirin.

show abstract

The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It

Cited by 97 publications

References 276 publications

Breast Cancer and Its Relationship with the Microbiota

Breast Cancer and Its Relationship with the Microbiota

Microbiome and Breast Cancer: New Role for an Ancient Population

Complex roles of the old drug aspirin in cancer chemoprevention and therapy

Contact Info

Product

Resources

About